Not all codon optimization algorithms are created equal. GeneGPS eliminates bias, incorrect assumptions and flawed optimization strategies by focusing on what matters - what has been experimentally demonstrated to improve expression!
GeneGPS begins with a training set of systematically varied synthetic gene variants, whose expression is experimentally tested in a target host. The expression data is analyzed using machine learning to develop a gene design algorithm for that host. Genes designed using GeneGPS reliably outperform genes designed using alternative methods.
The GeneGPS technology is protected by issued US patents 7561972, 7561973, 8126653, 8401798 and pending applications.
We have built GeneGPS optimization algorithms for many bacterial, yeast, insect, plant, fungal and mammalian expression hosts. We continue to develop GeneGPS for novel expression hosts.
Gene variants optimized by GeneGPS express up to 10-fold more protein in E. coli than variants created using competitors' algorithms (high CAI, matching host bias, etc.).
Gene optimization without vector optimization is to leave the job half done. Vector elements can improve protein solubility, reduce aggregation, direct proteins to the correct compartment, mediate genetic stability and contribute to host cell health, as well as increasing expression yield.
Our extensive Vectorology® collection of vector elements include promoters, terminators, genetic insulators, RNA processing sequences, secretion signal sequences, solubility and affinity tags, selectable markers and bacterial and eukaryotic origins of replication. With VectorGPS we combine these Vectorology elements systematically, test the resulting vectors experimentally, and use machine learning analysis of the data to identify the best combinations of elements.
We have developed many ready-to-use expression vectors with superior performance in a wide range of hosts. We continue to apply VectorGPS to design custom vectors for novel hosts and applications.
ATUM expression vectors typically outperform commercially-available vectors (pCDNA3.4, pTT5) for the transient expression of GFP in HEK293 (v1, v2), ExpiCHO (v5, v6) and in both HEK293 and ExpiCHO (v3, v4).
Coupling gene optimization and vector design gives you the greatest chances of obtaining a highly performing expression construct.
A 5-fold improvement in titer of antibody in HEK293 delivered by combining vector and gene optimization.